Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Bullboard Posts
Comment by Redbaron2211on Aug 11, 2020 12:10am
196 Views
Post# 31390982

RE:RE:RE:no exogenous insulin supplementation???

RE:RE:RE:no exogenous insulin supplementation???I have to agree with Bio the only reason they use Insulin is because it takes time to figure out the dosing, they need to use small doses as they hone it in. 

Last fall the NR measuring C-petide says it all it's been confirmed that islets are abundant and highly vascularized surviving long term producing insulin.  Now it's just a matter of getting quantity right and takes some time.  It's good news if they have found the right dose but nothing ground breaking... That news was last fall....
 
Bio looking back at March 24th they were spot on and have actually fulfilled 2 of their highlighted collaborations (medtech, and academic).  Who knows maybe good things come in 3's.  
 
" Sernova's current collaborations with leading pharma, medtech, and academic researchers are progressing according to plan. We continue to field collaboration inquiries from other international and large regional pharma companies. " 
Bullboard Posts